RCEL vs. RXST, CBLL, EMBC, DCTH, BFLY, AVNS, BVS, AXGN, KIDS, and NPCE
Should you be buying AVITA Medical stock or one of its competitors? The main competitors of AVITA Medical include RxSight (RXST), CeriBell (CBLL), Embecta (EMBC), Delcath Systems (DCTH), Butterfly Network (BFLY), Avanos Medical (AVNS), Bioventus (BVS), AxoGen (AXGN), OrthoPediatrics (KIDS), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry.
AVITA Medical vs.
AVITA Medical (NASDAQ:RCEL) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
In the previous week, AVITA Medical had 4 more articles in the media than RxSight. MarketBeat recorded 5 mentions for AVITA Medical and 1 mentions for RxSight. RxSight's average media sentiment score of 1.90 beat AVITA Medical's score of 0.34 indicating that RxSight is being referred to more favorably in the news media.
AVITA Medical has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.
RxSight has higher revenue and earnings than AVITA Medical. RxSight is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.
27.7% of AVITA Medical shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 1.8% of AVITA Medical shares are owned by insiders. Comparatively, 9.4% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
AVITA Medical received 32 more outperform votes than RxSight when rated by MarketBeat users. Likewise, 70.59% of users gave AVITA Medical an outperform vote while only 63.41% of users gave RxSight an outperform vote.
AVITA Medical presently has a consensus price target of $16.50, suggesting a potential upside of 175.46%. RxSight has a consensus price target of $37.90, suggesting a potential upside of 141.56%. Given AVITA Medical's stronger consensus rating and higher probable upside, analysts clearly believe AVITA Medical is more favorable than RxSight.
RxSight has a net margin of -23.92% compared to AVITA Medical's net margin of -96.26%. RxSight's return on equity of -14.00% beat AVITA Medical's return on equity.
Summary
RxSight beats AVITA Medical on 11 of the 18 factors compared between the two stocks.
Get AVITA Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AVITA Medical Competitors List
Related Companies and Tools
This page (NASDAQ:RCEL) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy RCEL Stock Free RCEL Stock Alerts